The National Eye Institute Visual Function Question naire-25 , Impact of Vision Impairment and Treatment Satisfaction Survey-Intraocular Pressure had the highest number of positive ratings in the content validity assessment .
Conclusion This study provides a descriptive catalogue of vision-specific PRO instruments , to inform the choice of an appropriate measure of patient-reported outcomes in a glaucoma context
Purpose To identify  vision Patient-Reported Outcomes instruments relevant to glaucoma and assess their content validity .
Effectiveness and Safety of Brimonidine as Adjunctive Therapy for Patients With Elevated Intraocular Pressure in a Large, Open-label Community Trial
Purpose To determine the effectiveness and safety of brimonidine when used in combination with one or more glaucoma medications in patients with glaucoma or ocular hypertension . Methods Post hoc analysis of a multicenter , 2-month , open-label , prospect i ve , clinical trial in which 2,335 patients received brimonidine as monotherapy , replacement therapy , or combination therapy . Patients who received brimonidine as combination therapy ( n = 554 ) were examined in the current analysis . Efficacy was determined by the reduction in intraocular pressure ( IOP ) from baseline before the addition of brimonidine .  Safety and tolerability parameters included adverse events and quality -of-life measures ( e.g. , ocular comfort , energy level , breathing ability , night vision ) . Results Addition of brimonidine to preexisting regimens result ed in an overall mean additional reduction in IOP of 17.9 % ( 4.26 mm Hg ) at month 2 ( P < 0.001 ) . Significant additional IOP lowering was provided by brimonidine in combination with each preexisting regimen evaluated ( P ≤ 0.061 ) . When brimonidine was added to monotherapy with a nonselective & bgr;-blocker , the mean additional IOP reduction was 15.5 % ( 3.61 mm Hg , P < 0.001 ) . Addition of brimonidine to latanoprost monotherapy provided a 32.2 % ( 5.89 mm Hg ) mean additional IOP reduction ( P < 0.001 ) . Addition of brimonidine to combination regimens that included latanoprost provided additional mean decreases in IOP ranging from 15.5 % ( 3.63 mm Hg , P < 0.002 ) to 20.1 % ( 6.62 mm Hg , P < 0.001 ) . All quality -of-life parameters remained high or improved during the study . Mild to moderate adverse events were reported in 5.23 % of patients ( 29 of 552 ) ; 98.1 % of physicians rated brimonidine adjunctive therapy as good or excellent . Conclusions Brimonidine , when added to existing glaucoma regimens , safely and effectively lowered IOP in this community-based trial
The National Eye Institute Visual Function Question naire-25 , Impact of Vision Impairment and Treatment Satisfaction Survey-Intraocular Pressure had the highest number of positive ratings in the content validity assessment .
Conclusion This study provides a descriptive catalogue of vision-specific PRO instruments , to inform the choice of an appropriate measure of patient-reported outcomes in a glaucoma context
Purpose To identify  vision Patient-Reported Outcomes instruments relevant to glaucoma and assess their content validity .